Individual results vary, and DSIP is not appropriate for everyone: People with chronic insomnia that has not responded adequately to behavioral or conventional pharmacological interventions Shift workers or frequent travelers are dealing with circadian rhythm disruption Individuals experiencing stress-related sleep disturbances and elevated cortisol patterns Athletes and active individuals seeking to optimize recovery through improved sleep quality Older adults experiencing age-related changes in sleep architecture and hormone secretion People who have experienced side effects from traditional sleep medications and are seeking non-sedating alternatives Individuals managing chronic pain conditions that interfere with restorative sleep Struggling with sleep and recovery
Zhang W, Doherty M, Bardin T, et al
The well-known, Ozempic (brand name for semaglutide), belongs to a group of drugs known as GLP-1 receptor agonists
GLP-1 receptors are expressed on up to 70% cerebral arterioles [18] and endothelial cells, and experimental models demonstrate that GLP-1 signaling promotes arteriolar vasodilation, improved endothelial nitric oxide signaling, and angiogenic pathways such as VEGF upregulation, all of which enhance nutrient and oxygen delivery to metabolically active brain regions [13,14]
Research suggests they can help support liver function, digestive tract health, the immune system, and more
Without affecting blood sugar, glucose, or muscle mass, early studies showed that AOD-9604 efficiently improves fat loss by improving lipid metabolism and blocking lipogenesis (1)